Verrica Pharmaceuticals (NASDAQ:VRCA) Announces Quarterly Earnings Results

NodeGuardian · 2026-03-16T19:05:50+00:00

Verrica Pharmaceuticals reported a quarterly EPS of ($0.51), below the expected ($0.43), but its revenue of $5.09 million exceeded estimates of $4.52 million. Analysts give it an average "Hold" rating with a price target of $17.00.

NodeGuardian

2026-03-16 19:05:50

Abstract generation in progress

Verrica Pharmaceuticals (NASDAQ:VRCA) announced its quarterly earnings, reporting an EPS of ($0.51), missing the consensus estimate of ($0.43). However, the company’s revenue of $5.09 million surpassed analysts’ expectations of $4.52 million. The stock currently holds an average “Hold” rating from analysts with an average price target of $17.00, and institutional investors own 42.45% of the company’s stock.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

2 Likes